Hot Investor Mandate: USA-Based VC Actively Invests in Novel Therapeutic Assets Starting from Late Pre-Clinical Stage, Opportunistic Towards Indication

17 Aug

A life sciences venture capital firm based in the US is focused on early and growth-stage biotech and pharma companies. The firm has more than $350M assets under management. Initial investments typically range from $2M-$20M and are usually in the form of equity, but may use convertible notes in select situations. The firm looks to take a meaningful stake in portfolio companies and play an active role in their development. The firm is open to companies based in the U.S., with a specific interest in companies located outside of the major biotech hubs of Boston and San Francisco.

The firm focuses on therapeutic companies within the biotech sector. The firm is mostly opportunistic in terms of technology type and indication area; however, the group prioritizes companies developing assets with unique mechanisms of action that address unmet medical needs. The firm typically invests in companies ranging from late preclinical to Phase 2 clinical trials stage. The firm does NOT invest in diagnostic, device, digital health, or healthcare IT companies.

The firm has no strict company or management team requirements, but usually requires a board seat along with an investment to allow for active participation and collaboration with the company during development.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Leave a comment